What is Mologic?
Mologic operates at the intersection of biotechnology and medical device engineering, specializing in the development of rapid diagnostic products. Since re-establishing its independence in 2014, the company has cultivated a diverse portfolio that includes respiratory disease monitors and advanced vaccine innovation technologies. Beyond its internal product development, Mologic functions as a high-value contract partner, offering end-to-end services that span from initial conceptualization to ISO13485-certified low-volume manufacturing. This dual-model approach—combining proprietary product development with specialized contract services—positions Mologic as a versatile and essential partner within the global healthcare supply chain.
How much funding has Mologic raised?
Mologic has raised a total of $14.9M across 4 funding rounds:
Private Equity
$4.6M
Series A
$4.6M
Grant
$4.8M
Series B
$915K
Private Equity (2015): $4.6M with participation from Calculus Capital
Series A (2015): $4.6M led by Calculus Capital
Grant (2016): $4.8M supported by Bill & Melinda Gates Foundation
Series B (2018): $915K featuring Innovate UK
Key Investors in Mologic
Bill & Melinda Gates Foundation
A global philanthropic organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives through strategic health investments.
Calculus Capital
A London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, with a focus on high-growth technology and healthcare businesses.
Innovate UK
The UK's national innovation agency, which provides grant-in-aid funding to support research and development projects that drive economic growth and technological advancement.
What's next for Mologic?
With the recent influx of capital, Mologic is well-positioned to accelerate the commercialization of its remaining product pipeline and expand its footprint in the respiratory disease monitoring market. The strategic focus will likely shift toward scaling manufacturing capabilities and strengthening international distribution networks to support the global rollout of its diagnostic portfolio. Furthermore, the company is expected to deepen its investment in vaccine innovation and large animal diagnostics, leveraging its existing technological infrastructure to address unmet needs in veterinary and public health. As Mologic continues to refine its harmonized service model, it remains a prime candidate for further strategic partnerships and potential market consolidation within the diagnostic technology sector.
See full Mologic company page
